Designing and evaluating large language model-enabled clinical decision support for heart failure: a modular and risk-tiered framework - Report - MDSpire

Designing and evaluating large language model-enabled clinical decision support for heart failure: a modular and risk-tiered framework

  • By

  • Wenfang Zhu

  • Jin Peng

  • Zhi Yan

  • Yuhong Chen

  • Jinpeng Xu

  • Liang Zhang

  • June 4, 2026

  • 0 min

Share

Developing and Assessing a Modular, Risk-Based Framework for Clinical Decision Support in Heart Failure Using Large Language Models

Overview

Revise to focus solely on the features of the HF-IA framework without claims of effectiveness.

Background

Remove speculative language regarding the benefits of LLMs in clinical decision support.

Data Highlights

No numerical data or trial data were provided in the source material.

Key Findings

  • The HF-IA framework is modular, allowing for tailored decision support across different aspects of heart failure care.
  • Evaluation of LLM-based CDS should incorporate diverse testing methods, including longitudinal case replay and post-deployment monitoring.
  • Different clinical tasks in heart failure management require distinct data inputs and reference standards.
  • LLMs can process unstructured data and assist in synthesizing patient-specific information for clinical decision-making.
  • Safety concerns arise when LLMs provide reasonable answers that may overlook critical clinical indicators.

Clinical Implications

The HF-IA framework provides a structured approach for integrating LLMs into heart failure management, emphasizing the importance of modular design and comprehensive evaluation. Clinicians should be aware of the varying data requirements and potential risks associated with LLM-generated recommendations.

Conclusion

Revise to eliminate unsupported claims about the framework's significance and research needs.

Related Resources & Content

  1. npj Digital Medicine, 2026 -- Benchmarking large language model-based agent systems for clinical decision tasks
  2. npj Digital Medicine, 2026 -- Enhanced Transferability of Predictions from Electronic Health Records Across Different Countries and Coding Frameworks Using Large Language Models
  3. npj Digital Medicine, 2025 -- A New Benchmark for Assessing Safety and Efficacy of Medical Large Language Models in Clinical Settings
  4. Frontiers in Medicine, 2026 -- Heart failure risk prediction based on machine learning and interpretability analysis
  5. American College of Cardiology -- Guidelines and Clinical Policy
  6. JACC, 2025 -- 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
  7. ESC, 2023 -- 2023 Focused Update on Heart Failure
  8. ISHLT -- New ISHLT Guideline on the Care and Evaluation of Heart Transplant Candidates
  9. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity - PubMed
  10. Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial | JACC
  11. Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial | JAMA
  12. Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis - PubMed
  13. Non-invasive telemonitoring programs for patients with chronic heart failure: A systematic review and meta-analysis of randomized controlled trials - PubMed
  14. Guidelines and Clinical Policy - American College of Cardiology
  15. 2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology | JACC
  16. 2023 Focused Update on Heart Failure
  17. New ISHLT Guideline on the Care and Evaluation of Heart Transplant Candidates | ISHLT
  18. Clinical Decision Support Software - Final Guidance
  19. Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions | FDA
  20. Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, & Tools for Risk of Cardiovascular Disease - Professional Heart Daily | American Heart Association

Original Source(s)

Related Content